(AP) The Food and Drug Administration has issued a positive review for a highly anticipated hepatitis C drug from Gilead Sciences, saying the pill cures more patients in less time than currently available treatments.
The agency posted its review of Gilead's sofosbuvir online ahead of a meeting Friday where government experts will vote on whether to recommend the drug's approval.
More than 3 million people in the U.S. have Hepatitis C, a blood-borne disease that causes liver damage and is blamed for 15,000 deaths a year. The drugs currently used to treat the virus cure about 65 to 75 percent of people and can take up to a year of treatment.
FDA said sofosbuvir cured 90 percent of patients with the most common form of the virus in just 12 weeks.